GSA Capital Partners LLP grew its holdings in Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Rating) by 97.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,894 shares of the company's stock after purchasing an additional 11,303 shares during the period. GSA Capital Partners LLP owned about 0.07% of Silverback Therapeutics worth $80,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in SBTX. Avantax Planning Partners Inc. acquired a new position in Silverback Therapeutics during the first quarter worth $113,000. Allspring Global Investments Holdings LLC acquired a new position in Silverback Therapeutics during the first quarter worth $142,000. Bailard Inc. acquired a new position in Silverback Therapeutics during the fourth quarter worth $213,000. IndexIQ Advisors LLC acquired a new position in Silverback Therapeutics during the first quarter worth $398,000. Finally, Acadian Asset Management LLC acquired a new position in Silverback Therapeutics during the fourth quarter worth $522,000. 74.89% of the stock is currently owned by institutional investors and hedge funds.
Get Silverback Therapeutics alerts:Analysts Set New Price Targets
Separately, Stifel Nicolaus lowered their target price on shares of Silverback Therapeutics from $6.00 to $5.00 in a report on Friday, May 13th. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $33.00.
Silverback Therapeutics Price Performance
NASDAQ:SBTX opened at $5.17 on Friday. Silverback Therapeutics, Inc. has a one year low of $2.80 and a one year high of $23.33. The company has a market cap of $183.40 million, a P/E ratio of -2.01 and a beta of 0.65. The firm's fifty day moving average price is $4.78 and its two-hundred day moving average price is $4.02.About Silverback Therapeutics
(Get Rating)
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Further Reading
- Get a free copy of the StockNews.com research report on Silverback Therapeutics (SBTX)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.